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ABSTRACT 
The immunoglobulin heavy chain intron enhancer (Eµ)
not only stimulates transcription but also V(D)J recom-
bination of chromosomally integrated recombination
substrates. We aimed at reproducing this effect in
recombination competent cells by transient transfec-
tion of extrachromosomal substrates. These we pre-
pared by interposing between the recombination
signal sequences (RSS) of the plasmid pBlueRec
various fragments, including Eµ, possibly affecting
V(D)J recombination. Our work shows that sequences
inserted between RSS 23 and RSS 12, with distances
from their proximal ends of 26 and 284 bp respectively,
can markedly affect the frequency of V(D)J recombina-
tion. We report that the entire Eµ, the Eµ core as well as
its flanking 5′ and 3′ matrix associated regions (5′ and
3′ MARs) upregulate V(D)J recombination while the
downstream section of the 3′ MAR of Eµ does not. Also,
prokaryotic sequences markedly suppress V(D)J
recombination. This confirms previous results
obtained with chromosomally integrated substrates,
except for the finding that the full length 3′ MAR of Eµ
stimulates V(D)J recombination in an episomal but not
in a chromosomal context. The fact that other MARs do
not share this activity suggests that the effect is not
mediated through attachment of the recombination
substrate to a nuclear matrix-associated recombina-
tion complex but through cis-activation. The presence
of a 26 bp A–T-rich sequence motif in the 5′ and 3′
MARs of Eµ and in all of the other upregulating
fragments investigated, leads us to propose that the
motif represents a novel recombinational enhancer
element distinct from those constituting the Eµ core.
INTRODUCTION
Antibody diversity is generated to a large extent by recombination
of DNA segments termed V, D and J (1–3). Functional
immunoglobulin genes are formed during this event. With reference
to the DNA segments involved the process is known as V(D)J
recombination. Much progress has been made towards the
elucidation of the underlying basic mechanism (4–16). In
contrast, little is known about its regulation (17–30).
It has been shown that immunoglobulin κ and µ chain intron
enhancers not only stimulate transcription but also V(D)J
recombination (20–23,27–29). Similar observations have been
made with the λ light chain enhancer located 3′ of Cλ (31) and
the T cell receptor α and β chain enhancers (32–34). The
stimulation of V(D)J recombination by the immunoglobulin
heavy chain intron enhancer (Eµ) can be dissociated from the
enhancement of transcription (28) demonstrating that recombina-
tional enhancement is not simply the result of an elevated
transcription with consequent opening of the chromatin conforma-
tion. These studies have been performed in stably transfected cells
or transgenic mice with chromosomally integrated recombination
substrates containing variously mutated enhancers in cis. These
systems do not lend themselves to easy manipulation and rapid
screening of potentially regulating sequences. In the present work
we have attempted to circumvent this problem by using a more
convenient assay based on transient transfections of variously
modified plasmid recombination substrates.
MATERIALS AND METHODS 
Plasmid constructs
All plasmid constructs were based on the recombination substrate
pBlueRec (35). This plasmid contains a lacZ(α) gene interrupted
by a DNA fragment flanked by consensus recombination signal
sequences (RSS) on both sides (Fig. 1).
Potentially regulating elements were inserted into the unique
EcoRV site downstream of the RSS 23 by blunt end ligation
(Fig. 1). After subcloning, the presence and orientation of the
inserts were checked by restriction enzyme analysis. Lambda
phage inserts were restriction fragments NarI (corresponding to
nucleotides 45 680–48 502 of the lambda genome, EMBL
accession no. V00636) and HincII (nucleotides 28 928–31 809,
accession no. V00636). MII (36; accession no. L23999) and E3
(37; an earlier incomplete version is deposited in the EMBL data
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Figure 1. Map of the V(D)J recombination substrate, pBlueRec. Sequences to
be tested for effects on the frequency of V(D)J recombination (Table 1) were
inserted into the unique EcoRV site. Numbers refer to map positions as defined
earlier (35). RSS, recombination signal sequence.
base under accession no. M60688, an updated version can be
accessed in the data base of the National Center for Genome
Resources http://www.ncgr.org/cgi-bin/ff?accloc=M60688) were
cut from their vectors by EcoRI–BamHI and EcoRI, respectively.
BX2.95 (38) was obtained as a BamHI–XbaI fragment (39). The
fushi tarazu MAR insert (40) was an EcoRI fragment cut out of
a Carnegie based construct carrying the Drosophila fushi tarazu
gene. Eµ was cut from the corresponding OVEC construct by
XbaI digestion (41,42; accession no. M12827). Subfragments of
Eµ were obtained by digestion with XbaI + PstI or with XbaI + HinfI
or with XbaI + EcoRI. The SV40 enhancer was cut from an
OVEC construct by PvuII + XhoI digestion (nucleotides
100–272, accession no. J02400). The CMV enhancer was cut
from CMV-lacZ by SacI + BamHI (nucleotides 173 773–174 255,
accession no. X17403). The 54 bp sequence of an established
topoisomerase II cutting site originating from the human β globin
gene (43) was subcloned in the same EcoRV site of pBlueRec by
a PCR strategy with asymmetric primers.
Cell culture
Pre-B cell lines 38B9, 1-8 and 300-19 (44) were cultivated in
HEPES buffered RPMI 1640 medium containing 2 mM Gluta-
max, supplemented with 10% foetal calf serum, 100 U/ml
penicillin, 100 µg/ml streptomycin and 50 µM β-mercaptoethanol
(Gibco Life Technologies). Recombination-competent 31.7.12 cells
(M12 lymphoma cells with stably integrated RAG1 and RAG2
genes driven by a heat-inducible promoter and a mutated dhfr
gene allowing selection with the folate analogue methotrexate;
45) were grown in the above RPMI medium containing 100 mM
methotrexate (Calbiochem). All cell lines were grown at 37C in
a 6% CO2 atmosphere.
V(D)J recombination assay
The assay exploits the fact that the substrate contains an
interrupted lacZ(α) gene, the reading frame of which is restored
by V(D)J recombination (Fig. 1). Thus, upon transformation of
Escherichia coli XL1 blue with the reaction products the
recombination frequency, R, can be determined by dividing the
number of blue colonies by the sum of blue and white colonies
which grow on X-gal/IPTG agar plates.
Plasmid constructs were transiently transfected into recombina-
tion-competent cells by the DEAE–dextran method (46). Briefly,
3 × 106 viable cells were washed in PBS and incubated at 37C
in 0.5 ml of the following transfection mixture: 67% (v/v) RPMI
1640, 0.25 mg/ml DEAE–dextran (Sigma), 50 mM Tris–HCl pH
7.4 and 0.5–1 µg DNA. After 10 min, the cells were spun for 5 min
at 300 g and resuspended in RPMI 1640, then spun again and
finally resuspended in the above medium for a further 48 h at
37C in a 6% CO2 atmosphere.
Plasmid DNA was recovered from the cells by alkaline lysis,
deproteinized by phenol–chloroform extraction and precipitated
with isopropanol followed by centrifugation for 15 min in a
refrigerated microcentrifuge. Pellets were washed in 80% ethanol,
dried in open air and dissolved in 20 µl TE buffer (47). Aliquots
of 10 µl were digested for 30 min at 37C with 5 U DpnI (New
England Biolabs) in order to remove unreplicated plasmids that
might not have entered the cells.
The digest was allowed to transform 200 µl of freshly thawed
competent E.coli XL1 blue strain (Stratagene) for 1 h on ice. The
transformation mixture was heat shocked for 40 s at 42C,
returned to ice and supplemented with 0.8 ml of cold SOC
medium before incubation for 1 h at 37C in a shaking incubator
(48). The whole mixture was plated on LB-agar plates containing
100 µg/ml ampicillin (Sigma), 40 µg/ml X-gal and 50 µg/ml
IPTG (Bachem Feinchemikalien) and incubated overnight at 37C.
Blue and white colonies were counted separately on a negatoscope
and on a black screen, respectively.
Statistics
Duplicate transfections were done in parallel followed by
transformation into XL1 blue. The resulting blue colonies from
the duplicates were summed and divided by the total number of
colonies to give a single r value. Independent transfection
experiments (each consisting of duplicates) were performed on at
least 3 separate days, each giving a separate r value. To arrive at
an overall recombination frequency, R, the separate r values from
independent transfection experiments were averaged and the
standard deviation (SD) determined. Fold stimulation was
calculated for each independent transfection experiment by
dividing r experimental by r control, i.e. the r for pBlueRec
obtained in parallel transfections. The individual fold stimulation
values of all transfection experiments with a particular insert were
then averaged and the SD determined. This normalization of R
values allows comparison of different experiments (49).
In situ hybridization on colony lifts
While analyzing Eµ and its subfragments, it became apparent that
the V(D)J recombination assay based on the counting of blue and
white colonies could not be applied to the constructs carrying the
XbaI–HinfI and XbaI–PstI subfragments in the genomic (+)
orientation. With these subfragments (and only with these)
colonies were difficult to identify as either white or blue owing
to the presence of a high proportion of colonies with intermediate
hue. When amplified by PCR, a significant number of them
displayed a 500 bp band characteristic of non-recombined plasmids
further compromising the β-galactosidase assay.
We therefore developed an alternative recombination assay
based on in situ hybridization of colony lifts. A 29 bp oligonucleo-
tide probe was designed which would hybridize to the coding
joint of recombined plasmids but not to non-recombined
substrates. The probe sequence (5′-AGAACTAGTGGAIIIIIIG-
ACCTCGAGGG-3′) was complementary to the lacZ(α) sequence
bracketing the coding joint and contained six interposed inosines
allowing for hybridization even with processed joints. When
checked on identified plasmids recovered from cell extracts and
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Table 1. Sequences tested for effects on the frequency of V(D)J
recombination in 38B9 cells
aInsert in genomic (+) or inverted (–) orientation relative to direction of lacZ
transcription. IgH, immunoglobulin heavy chain; enh, enhancer; topo, topo-
isomerase; topo II site, topoisomerase II cutting site; Eµ, immunoglobulin
heavy chain intron enhancer; P, PstI; Xb, XbaI; EI, EcoRI; Hf, HinfI; Xh, XhoI.
bPercent recombination frequency.
cFold stimulation was calculated relative to control pBlueRec as described in
Materials and Methods (Statistics). For statistical reasons, the ratio obtainable
by dividing the mean of Experimental R × 100 by the mean of Control R × 100
would deviate from the correctly determined value of Fold stimulation as
given in the table.
dp values identify entries where R Experimental differs significantly from R
Control; calculation was by t-test.
eValues obtained by in situ hybridization on colony lifts.
amplified by PCR, this oligoprobe hybridized to 70–80% of the
recombined plasmids (40 out of 52 analyzed).
To perform the assay, colony lifts were taken on Nylon A
membranes (PALL, Biodyne), denatured for 5 min with 1.5 M
NaCl/ 0.5 M NaOH, drained, and neutralized for 5 min with 1.5 M
NaCl/0.5 M Tris (pH 7.4). Nucleic acids were crosslinked to the
membrane by UV light, and proteins were removed by overnight
digestion with 100 µg/ml proteinase K at 37C. After prehybridiz-
ation for 2 h at 60C, membranes were hybridized overnight at
60C with the 32P-end-labelled oligonucleotide probe (6 × 106
c.p.m./ml). Washings were performed for 10 min in 2% SSC and
for 25 min in 1% SSC/0.1% SDS at room temperature followed
by a final wash in 0.1% SSC/0.1% SDS for 30 min at 50C.
Computer search for sequence homology
The Wisconsin package GCG software was used. A search for
homologous sequences among the upregulating fragments was
performed with the programmes ‘compare’, ‘dotplot’ and ‘bestfit’
using standard settings. This yielded a 26 bp consensus motif, the
occurrence of which was probed for in all other fragments using
the command ‘findpattern’. The entire EMBL and GenBank
databases were then searched using the programme BLASTN.
RESULTS 
The mouse heavy chain intron enhancer, Eµ, upregulates
V(D)J recombination
Table 1 summarizes the recombination frequencies registered
after transient transfection of the pre-B cell line 38B9 with various
recombination substrates. The latter were obtained by inserting
potentially regulating sequences and corresponding controls into
the unique EcoRV site of the plasmid, pBlueRec (Fig. 1).
The composite sequence of the entire Eµ (XbaI–XbaI fragment;
Fig. 2) stimulated V(D)J recombination ∼4-fold when inserted in
the genomic orientation and ∼2-fold in the inverted orientation
(Table 1). This compares well with a factor of ∼5 determined in
a more physiological context for a rearrangement-enhancing
element upstream of the mouse immunoglobulin κ chain J cluster
(50). In contrast, the SV40 enhancer had no effect, and the CMV
enhancer even decreased the recombination frequency. It should
be noted that in a chromosomal context the SV40 enhancer has
been found to stimulate V(D)J recombination (23).
Upregulation by Eµ is conferred both by the core enhancer
and by its flanking matrix associated regions
To delineate which parts of Eµ were responsible for the observed
stimulation, we prepared various Eµ subfragments carrying either
the core enhancer, the matrix associated regions (5′ MAR or 3′
MAR) or combinations thereof (Fig. 2). Increased recombination
frequencies were observed both with the core enhancer and with
fragments containing either the 5′ MAR, the intact (but not the
truncated) 3′ MAR or composite sequences of either MAR with
the core enhancer (Table 1 and Fig. 2). With the exception of the
5′ MAR this effect was clearly orientation dependent.
Our finding of an upregulating effect of the isolated core
enhancer is in accord with the observation that a minimal version
of Eµ is sufficient to target a chromosomally integrated substrate
for V(D)J recombination (23). It also reflects earlier results
showing that two small deletions in the Eµ core abolish V(D)J
recombination in a transgenic substrate (28). Similarly, activation
by the 5′ MAR agrees with a previous report showing that
targeted disruption of the 5′ MAR in a chromosomal context
dramatically decreased recombination of the linked JH locus (21).
Our observation that the truncated 3′ MAR (the fragment
EµEIXb) does not affect the frequency of V(D)J recombination
also agrees with the results of transgenic experiments (21).
In contrast, discrepant results were obtained with respect to the
entire 3′ MAR, which stimulated V(D)J recombination in our
system but not in a transgenic substrate (27,28).
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Figure 2. Eµ and its subfragments acting on recombination frequency. The top graph is a map of the known transcription elements and identifies the enhancer core
with flanking 5′ and 3′ MARs (51). In Eµ, filled arrowheads with numbers indicate the positions and orientations of a 26 bp A–T-rich sequence motif (Fig. 3); orientation
refers to the 5′→3′ direction in the plus and minus strand, respectively.
Matrix associated regions do not in general upregulate
V(D)J recombination
We asked whether, in our system, upregulation of V(D)J
recombination was a general property of MARs. To answer this
question we tested for the effects of MAR sequences derived from
sources other than Eµ. We chose MARs associated with the genes
of human topoisomerase I, chicken lysozyme and Drosophila
fushi tarazu. Recombination was significantly increased with the
MAR (termed MII) from intron 13 of the human topoisomerase
I gene, but only when it was inserted in genomic orientation
(Table 1). The chicken lysozyme MAR even reduced the
frequency of recombination, while the Drosophila fushi tarazu
MAR remained without effect. Thus, MARs do not in general
upregulate V(D)J recombination.
MARs often include clusters of topoisomerase II consensus
sequences. One possible explanation for the discordant effects of
the MARs tested might therefore be the presence or absence of
such sequences particularly in view of a conceivable participation
of topoisomerase II in V(D)J recombination. We therefore
inserted an established human topoisomerase II cutting site (top 2)
into the recombination substrate. As a result the recombination
frequency was reduced to half (Table 1), thus ruling against the
possibility that the presence of topoisomerase II cutting sites was
responsible for the upregulation of V(D)J recombination by some
MARs but not by others.
A non-MAR sequence, E3, upregulates V(D)J recombination
While investigating the influence of MARs on V(D)J recombination
(see preceding paragraph) we used a control sequence (E3) of
comparable length which had been proven to lack MAR activity
(52). Interestingly, this sequence stimulated V(D)J recombination
4-fold when inserted in genomic orientation (Table 1). This
finding further contradicted the possibility that, in our system,
MARs were required for high frequency recombination.
E3 is derived from the 5′ end of the human topoisomerase I
gene. It spans the promoter as well as exons 1 and 2, and extends
into the adjacent intron. By digesting with XhoI, E3 was split into
a 5′ fragment (termed topo I promoter), containing the entire
promoter with the 5′ half of exon 1 attached, and a 3′ fragment
(termed topo I coding) encompassing the remainder of E3. When
tested in the recombination assay (Table 1) the promoter part was
ineffective. In contrast, the coding part increased the recombination
frequency by a factor of 3, but only when inserted in antigenomic
orientation. This was surprising in light of the previous observation
that the entire E3 upregulated V(D)J recombination when inserted
in the opposite orientation.
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Table 2. Sequences tested for effects on frequency of V(D)J recombination
in 300-19, 1-8 and 31.7.12 cells
For explanations see Table 1 footnotes.
Two unrelated λ phage fragments were tested as additional
representatives of non-MAR sequences. They were selected so as
to be of similar length as the MARs and the E3 non-MAR described
above. These sequences strongly depressed V(D)J recombination in
either orientation. A suppressive effect of prokaryotic sequences
on V(D)J recombination has been described previously (27).
Other B cell lines respond similarly to a selection of test
inserts
Up to this point all experiments had been performed with the
Abelson murine virus-transformed pre-B cell line 38B9. It was of
interest to see whether the observed responses were cell line-
dependent or had a more general significance. We addressed this
question by transfecting other recombination-competent cell
lines with some of our recombination substrates selected for
maximum efficiency (Table 2).
We used the Abelson murine virus-transformed pre-B cell lines
1-8 and 300-19 as well as the mature B cell line 31.7.12, which
has been derived from M12 lymphoma cells by stable transfection
with full-length RAG1 and RAG2. Similar to 38B9, 1-8 cells
continuously rearrange their D–JH and VH–DJH loci, whereas
300-19 cells carry fully rearranged DJH loci. In the more mature
31.7.12 cells endogenous VDJ loci are fully rearranged.
A comparison of the results in Table 1 (38B9 cells) and Table 2
(1-8, 300–19, 31.7.12 cells) shows that the four cell lines respond
similarly to the inserts Eµ, MII, E3 and B1X1 in genomic
orientation. Upregulation is consistently observed with Eµ, MII
and E3, while B1X1 either downregulates V(D)J recombination
or leaves it unaffected. Thus, the effects are intrinsic to the inserted
sequences and are largely independent of cell stage and origin.
A 26 bp A–T-rich motif is common to all upregulating
sequences other than the Eµ core
A computer search was initiated for sequences common to all of
the upregulating inserts investigated. This led to the detection of
a 26 bp A–T-rich sequence motif characterized by the consensus
sequence shown in Figure 3 (bottom).
The motif occurred in Eµ, MII and E3 but was absent from all
other inserts. It appeared in 23 variants, six of which were
associated with Eµ (variants 1–6; numbering of the variants refers
to their position relative to the 5′ end of the insert; Fig. 2), 14 with
MII (variants 7–20) and three with E3 (variants 21–23). The
positions, orientations and sequences of these variants are listed
in Figure 3.
The variants were charted on their respective fragments. In Eµ,
the motif was restricted to the 5′ and 3′ MARs, not being present
in the core (Fig. 2). In MII, the variants were evenly distributed
over the entire length of the fragment, and in E3 were confined
to the topo I coding fragment.
Consistent with the possibility that the motif might represent a
novel upregulating element distinct from those constituting the
Eµ core, the motif was present in all fragments and subfragments
found to activate V(D)J recombination except the Eµ core. In
addition, the motif was absent from all inserts devoid of an
upregulating activity, with the single exception of the truncated
3′ MAR of Eµ (the subfragment EµEIXb) which, despite its
content of four copies of the motif, was inactive. This might be
explained by assuming that certain sequence features are
absolutely required for activity. In fact, closer scrutiny revealed
that all upregulating fragments contained at least one variant
carrying a 5′ terminal ACT triplet, while EµEIXb did not (5′ refers
to the sequence motif, irrespective of whether it is located in the
plus or minus strand of the insert, and does not specify its
orientation relative to the direction of lacZ transcription). The
triplet was present in variants 1 and 2 (Eµ), 9, 10, 16, 17 and 20 (MII)
as well as 23 (E3) but was missing from all others (Fig. 3). It is
generally recognized that functionally essential sequence character-
istics are often located at the ends of recognition elements [e.g. the
heptamer of the V(D)J recombination signal sequences; 53–55].
Alternatively, the activity of the motif may also vary depending
on orientation (as suggested by the results presented in Table 1)
and sequence context. In particular, the clustering and interdigitation
(in the case of variants 4 and 5) of the four plus and minus strand
variants contained in EµEIXb might abrogate the functions of the
individual copies.
The computer search was extended to the entire EMBL and
GenBank databases. Variants 1–6 (Eµ) were found to be unique
to the mouse immunoglobulin heavy chain intron enhancer.
Interestingly, a homologue of variant 6 with a T→C transition at
position 3 was detected in the mouse immunoglobulin heavy
chain switch region (accession no. J00478). Variants 7–20 (MII)
were restricted to the human topoisomerase I gene, except for
variant 12, which in addition was also associated with various
other human genes but was absent from other species. Variant 21
with flanks identical to those in E3 has been described previously
as part of a human CpG-containing DNA clone (accession no.
Z57072). Variants 22 and 23 (E3) were not contained in the
databases.
DISCUSSION
Previous studies with chromosomally integrated recombination
substrates have shown that V(D)J recombination is stimulated by
immunoglobulin and T cell receptor transcriptional enhancers
(20–23,27–29,31,32). In the case of Eµ, upregulation was found
to be associated with both the enhancer core (28) and the
5′-flanking MAR (21) and to be independent of the level of
transcription (28). To accelerate the search for recombinational
enhancer elements we have attempted to develop a simpler assay
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Figure 3. A 26 bp A–T-rich consensus sequence and its variants occurring in the upregulating inserts, Eµ, MII and E3. For the positions and orientations of variants
1–6 in Eµ, see also Figure 2. Shading indicates identity with consensus sequence. A 5′ terminal ACT triplet of potential functional significance is boxed. Similarity
is defined as the percentage of nucleotides corresponding to shaded positions in the consensus sequence.
based on the transient transfection of easily manipulatable
extrachromosomal recombination substrates.
To evaluate the reliability of such a system we first aimed at
reproducing in extra-chromosomal substrates the effects reported
for chromosomally integrated constructs containing variously
mutated enhancers in cis. For this purpose, we inserted the entire
Eµ and fragments thereof into the unique EcoRV site of the
plasmid substrate pBlueRec, and, following transfection into
recombination competent cells, determined the frequency of
recombination.
Consistent with previous reports we find that the entire Eµ
(21,22,27,28), the Eµ core (23,28) and the 5′-flanking MAR (21)
upregulate V(D)J recombination, whereas the downstream section
of the 3′ MAR (the fragment EµEIXb) has no effect (21). Also,
as described formerly (27), prokaryotic sequences derived from
λ phage markedly suppress V(D)J recombination. Thus, with all
of these constructs, our extrachromosomal assay accurately
reflects the situation with chromosomally integrated substrates. It
deviates from the latter only in two respects, namely that (i) the
extrachromosomal SV40 enhancer does not activate V(D)J
recombination (23), whereas (ii) the full-length 3′ MAR does
(27,28). The lack of activity of the SV40 enhancer might be
explained by the preexistence of a polyoma enhancer in the
recombination substrate, which might mask the effect of additional
viral enhancer elements. The same may be true for the CMV
enhancer. Such interference has previously been reported with the
κ enhancer (56). Alternatively, the SV40 enhancer might lack
specific recombinational enhancer elements necessary for
upregulating V(D)J recombination in an episomal context but, in
chromosomally integrated substrates, might stimulate recombina-
tion indirectly through activation of transcription with concomitant
opening of the chromatin conformation. The stimulating effect of
the extrachromosomal 3′ MAR is more difficult to explain.
Perhaps, in the transgenic substrates, the regulation of V(D)J
recombination is not entirely physiological with parts of the
enhancer being permanently silenced. In contrast, such shielding
by chromosomal proteins might not exist in extrachromosomal
substrates leaving the 3′ MAR enhancer sequences accessible to
activating proteins. It is important to note that our extrachromosomal
assay deviates from the chromosomal assays only if the latter
involve ectopically integrated recombination substrates
(23,27,28) but give results consistent with the more physiological
assays based on the targeted deletion or disruption of endogenous
enhancer sequences (21,22). Thus, the results presented in this
paper indicate that our extrachromosomal system is a valuable
alternative to the more elaborate assays based on chromosomally
integrated substrates.
The good agreement between the results of the present work
(episomal substrates) and those of previous studies (chromosomally
integrated substrates) is a strong indication that the effects we see
are not simply caused by methodological artefacts such as
different rates of plasmid replication in the transfected cells or
different efficiencies of transformation of E.coli. This is further
substantiated by the observation that the transformation efficiencies
were the same for all plasmids, and that all plasmids exhibited
identical replication rates except when carrying the MII insert in
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either orientation. Plasmids with this insert yielded lower
numbers of total (DpnI resistant) colonies than other plasmids, for
an equal number of plasmid molecules transfected. Decreased
replication of the substrate in comparison with the recombined
product could indeed mimic an increased recombination frequency.
However, if this were the explanation for the increased ratio of
recombined to total colonies observed with MII, then the same
result would be seen with MII in either orientation. This is not the
case (Table 1) rendering this interpretation of the data unlikely. It
certainly is invalid for all other inserts, none of which gave signs
of an altered replication rate.
The simplest statement that our work allows us to make is that
sequences interposed between a pair of RSS affect the frequency
of V(D)J recombination. Previous studies have dealt with the
influence of sequences immediately abutting the site of recombina-
tional cleavage on both sides (49,53–55,57,58) but medium and
long range effects of coding or non-coding elements have not
been investigated. In the present study, inserts were spaced 26 bp
from the RSS 23 and 284 bp from the RSS 12, respectively (Fig. 1),
and had lengths of 60–3200 bp (Table 1). With a minimal distance
of two and a half helix turns of DNA from the proximal end of the
nearest RSS (the RSS 23), it is improbable that the effects are due
to local DNA conformational changes such as unwinding or
bending of the RSS. Rather, they may be attributed either to an
altered flexibility of the DNA facilitating or impeding proper
synapsis of the recombination sites or to the presence of cis-acting
elements.
The activation of V(D)J recombination by the 5′ and 3′ MARs
of Eµ could be due to either of two mechanisms. For instance, the
MARs could bring about this effect by concentrating and
immobilizing the recombination substrate on the nuclear matrix,
thus bringing it into close proximity to a nuclear matrix-attached
recombination machinery acting upon it. Alternatively, the
MARs could stimulate recombination through cis-regulatory
elements. Our work suggests an answer to this question. If direct
attachment of recombination substrate to recombination complex
were the reason for the 5′ and 3′ MARs to stimulate V(D)J
recombination, then all MARs should exert this effect. This is
clearly not the case (Table 1) leading us to conclude that the 5′ and
3′ MARs of Eµ harbour recombinational enhancer elements.
Enhancers and MARs are known to act largely independent of
orientation. Thus, the observation that, in our assay, most of the
fragments exhibited orientation dependence requires explanation.
Assuming that the 5′ and 3′ MARs of Eµ mediate their effects
through recombinational enhancer elements the problem is
reduced to finding an explanation for enhancers. This could be
related to distance. In physiological conditions, enhancers are
located far remote from the elements they influence, e.g. promoters,
such that the interposed stretch of DNA can easily bend back
bringing enhancer and promoter complexes into contact. In
contrast, our inserts were comparatively short so that functional
interactions between proteins bound to asymmetrically positioned
enhancer elements and sites of recombination (the RSSs) might
be favoured in one of the two possible orientations and
disfavoured in the other. Alternatively, proteins binding to sites
close to one end of the insert might interfere with binding of the
recombinational enzyme complex in only one of the orientations
but not in the other (see next paragraph).
In a computer search for possible enhancer elements located in
the 5′ and 3′ MARs of Eµ, a 26 bp A–T-rich sequence motif
caught our attention (Fig. 3). It was present in all of the
upregulating fragments investigated except the Eµ core (Table 1
and Fig. 2). This suggested that the motif might be a novel
recombinational enhancer element distinct from those intrinsic to
the Eµ core. In agreement with this interpretation, the motif was
absent from all inactive fragments analyzed except the fragment
EµEIXb. The lack of activity of EµEIXb could be due to the fact
that none of the four motifs contained therein (variants 3–6)
carried a 5′ terminal ACT considered to be functionally essential
(see Results). Alternatively, the proximity of the RSS 23 to the
nearest motif (30 bp with variant 3 in the genomic orientation and
36 bp with variant 6 in the antigenomic orientation) might impede
the simultaneous binding of the recombinational enzyme complex
to the RSS and of its putative activator to the nearby motif.
The consensus sequence of the motif exactly corresponded to
the sequence of variant 1 located in the 5′ MAR of Eµ (Fig. 3).
A computer search revealed the motif (with an intact 5′ terminal
ACT triplet suggested to be essential for activity) to be restricted
to the murine Eµ and the human topoisomerase I gene. An
unrelated rearrangement-enhancing sequence element has been
detected recently upstream of the mouse immunoglobulin κ chain
J cluster (50). Its position between RSSs is comparable to the
location of the 26 bp A–T-rich motif in our recombination
substrates, and the enhancement of V(D)J recombination is of the
same magnitude in both systems. Although further work is
certainly needed to establish that the 26 bp A–T-rich motif is a
constituent of a recombinational enhancer, our findings may at
least provide a clue in the search for recombinational enhancer
elements.
If, indeed, the motif were to define a recombinational enhancer
element, what could be the reason for its occurrence in the human
topoisomerase I gene? It might be argued that the motif has a
function in association with RSSs only, thus lacking any
physiological role in the topoisomerase I gene. Alternatively, if
one accepts that the transcriptional enhancer, Eµ, also acts as a
recombinational enhancer, then it does not seem unreasonable to
postulate that a recombinational enhancer element in the immuno-
globulin gene might also function as a transcriptional enhancer
element in another gene, such as the topoisomerase I gene. One
might even speculate that this reflects a functional link between
V(D)J recombination and topoisomerase I transcription indicating
that topoisomerase I might be a component of the recombinational
complex.
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